XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $687K invested in XTL Biopharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0.34% more ownership
Funds ownership: 8.56% → 8.89% (+0.34%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
26% less capital invested
Capital invested by funds: $927K → $687K (-$240K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.9K |
| 2 |
Morgan Stanley
New York
|
+$186 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$371 |
XTLB Hedge Fund Activity: Q3 2019 in Review
6 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2019, worth a combined $687K — down 26% from $927K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.9K. The largest seller was UBS Group, cutting an estimated $371.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2019, up from 5 in Q2 2019.
- Funds reported $687K of XTL Biopharmaceuticals stock for Q3 2019, down 26% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q3 2019 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2019 was Citadel Advisors, an estimated $33.9K added.
- The largest XTL Biopharmaceuticals seller in Q3 2019 was UBS Group, an estimated $371 sold.
Based on aggregated 13F filings for Q3 2019.